GlassScriptPhysician profile
Richard Whitlock
NPI 1598797870
$2,443.43
in general payments reported to CMS, 2019-2025
26 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $14.17 · 2021: $74.35 · 2022: $38.91 · 2023: $266 · 2024: $812 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $348.53 | 2021-2025 | Freestyle Libre |
| Novo Nordisk INC | $329.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $260.36 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $246.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $203.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $167.68 | 2019-2025 | |
| Exact Sciences Corporation | $135.10 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $129.27 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $108.61 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $97.25 | 2019-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $59.60 | 2024 | |
| Amarin Pharma, INC. | $45.14 | 2019 | |
| Allergan, INC. | $41.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.95 | 2019 | |
| Merck Sharp & Dohme LLC | $27.90 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $26.73 | 2020-2021 | |
| Dexcom, INC. | $26.00 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $23.68 | 2019 | |
| Corcept Therapeutics | $21.86 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $20.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.82 | 2024 | Camzyos |
| Xeris Pharmaceuticals, INC. | $18.21 | 2024 | Gvoke Hypopen |
| Renalytix Ai, INC. | $15.96 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Janssen Pharmaceuticals, INC | $14.86 | 2019 | |
| Esperion Therapeutics, INC. | $14.70 | 2025 | Nexletol |
| Melinta Therapeutics, LLC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Whitlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.